Compass Therapeutics (NASDAQ:CMPX) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of Compass Therapeutics (NASDAQ:CMPX) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning.

Other equities research analysts also recently issued reports about the company. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Citizens Jmp restated a “market outperform” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 28th. Canaccord Genuity Group cut their price target on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Raymond James Financial cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.77.

Compass Therapeutics Stock Up 8.0%

Shares of CMPX stock opened at $2.15 on Friday. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The firm has a market capitalization of $387.19 million, a price-to-earnings ratio of -5.37 and a beta of 0.92. The firm has a fifty day moving average of $2.09 and a 200-day moving average of $3.86.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts expect that Compass Therapeutics will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Compass Therapeutics in the 2nd quarter valued at approximately $24,707,000. Deutsche Bank AG acquired a new stake in shares of Compass Therapeutics in the second quarter valued at approximately $294,000. Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics in the second quarter valued at approximately $80,000. Bank of New York Mellon Corp bought a new stake in shares of Compass Therapeutics in the second quarter worth $769,000. Finally, State of Wyoming acquired a new position in Compass Therapeutics during the second quarter worth $31,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Key Stories Impacting Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target on Compass Therapeutics from $4.00 to $6.00 and maintained an “overweight” rating. The new target implies substantial potential upside from recent trading levels, providing a positive catalyst for CMPX. Benzinga report
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $24.00 price target, indicating significant long-term optimism about Compass Therapeutics despite near-term forecast changes. The firm also raised its FY2028 EPS forecast modestly to a loss of $0.56 per share from a loss of $0.58. MarketBeat analyst estimates
• Neutral Sentiment: Analyst sentiment is mixed. Piper Sandler and HC Wainwright remain bullish, but HC Wainwright’s $24.00 target contrasts sharply with CMPX’s recent trading level, suggesting the valuation depends heavily on successful clinical and business execution.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for the near and medium term, now projecting losses of $0.15 per share in Q3 2026, $0.17 in Q4 2026 and $0.55 for FY2026, compared with its prior FY2026 loss estimate of $0.45. The FY2027 forecast was also lowered slightly to a $0.56 loss from $0.55, signaling expectations for continued cash burn.
• Negative Sentiment: Wall Street Zen reportedly downgraded Compass Therapeutics to “Strong Sell,” adding a bearish counterpoint to the favorable broker ratings and potentially increasing volatility in CMPX. Compass Therapeutics rating downgrade

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.